CAS 105026-50-4

morfolinoantraciclina MX2

Descripción:

morfolinoantraciclina MX2, con el número CAS 105026-50-4, es un derivado sintético de la antraciclina, una clase de compuestos conocidos por sus potentes propiedades antitumorales. Este compuesto presenta un grupo morfolino, que mejora su solubilidad y potencialmente altera su perfil farmacocinético en comparación con las antraciclinas tradicionales. morfolinoantraciclina MX2 exhibe un mecanismo de acción que típicamente implica la intercalación en el ADN, lo que lleva a la interrupción de los procesos de replicación y transcripción, induciendo finalmente la apoptosis en las células cancerosas. Sus modificaciones estructurales tienen como objetivo mejorar la selectividad y reducir la cardiotoxicidad, un efecto secundario común asociado con las antraciclinas convencionales. El compuesto se investiga principalmente por su eficacia contra diversas malignidades, y la investigación en curso se centra en su potencial terapéutico, regímenes de dosificación óptimos y perfiles de efectos secundarios. Al igual que con muchos agentes quimioterapéuticos, comprender su farmacodinámica y farmacocinética es crucial para maximizar sus beneficios clínicos mientras se minimizan los efectos adversos.

Fórmula: C₃₀H₃₅NO₁₁

InChI: InChI=1S/C30H35NO11/c1-3-30(39)12-17(42-18-11-15(24(33)13(2)41-18)31-7-9-40-10-8-31)20-23(29(30)38)28(37)21-22(27(20)36)26(35)19-14(25(21)34)5-4-6-16(19)32/h4-6,13,15,17-18,24,29,32-33,36-39H,3,7-12H2,1-2H3

Clave InChI: InChIKey=OPBPMGYBSDKJBT-UHFFFAOYSA-N

SMILES: OC=1C2=C(C(OC3CC(C(O)C(C)O3)N4CCOCC4)CC(CC)(O)C2O)C(O)=C5C1C(=O)C=6C(C5=O)=C(O)C=CC6

Sinónimos:

• (7R,8R,10S)-8-Ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione
• (7S-9R,10R)-3'-Deamino-3'-(4-morpholinyl)-13-deoxy-10-hydroxycarminomycin
• 3-Ethyl-3,4,5,10,12-Pentahydroxy-6,11-Dioxo-1,2,3,4,6,11-Hexahydrotetracen-1-Yl 2,3,6-Trideoxy-3-Morpholin-4-Ylhexopyranoside
• 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-8-ethyl-10-((3-(4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,6,7,8,11-pentahydroxy-
• 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-((2,3,6-trideoxy-3-(4-morpholinyl)-alpha-L-lyxo-hexopyranosyl)oxy)-
• 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-, (7R,8R,10S)-
• Antibiotic MX 2
• MX 2 (anthracycline)
• Morpholinyl oxaunomycin
• Mx 2
• [7S,9R,10R]-3′-Deamino-3′-(4-morpholinyl)-13-deoxo-10-hydroxycarminomycin
• 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-L-lyxo-hexopyranosyl]oxy]-, (7R,8R,10S)-
• Morpholinoanthracycline MX2

Anthracycline

CAS: 105026-50-4

Anthracycline is a class of chemotherapy drugs, which are anthraquinone antibiotics derived from the bacterial genus Streptomyces. They exert their therapeutic effects primarily through intercalation into DNA, disrupting the function of enzymes such as topoisomerase II, thus preventing the transcription and replication processes in rapidly dividing cancer cells. Furthermore, they generate free radicals, leading to oxidative stress and subsequent cell damage. These mechanisms collectively result in apoptosis of malignant cells. Anthracyclines are utilized extensively in oncology for the treatment of various malignancies, including leukemias, lymphomas, breast cancer, and sarcomas. The efficacy of anthracyclines in inhibiting tumor growth must be balanced against their cardiotoxic potential, which is a significant consideration in their clinical use. This dual nature makes them both pivotal and challenging in chemotherapy regimens, necessitating careful management and monitoring throughout treatment.

Fórmula: C₃₀H₃₅NO₁₁

Pureza: Min. 95%

Peso molecular: 585.60 g/mol

Ref: 3D-FA29742